Literature DB >> 21525187

Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1.

Tracy Tucker1, Vincent M Riccardi, Margaret Sutcliffe, Juergen Vielkind, Janine Wechsler, Pierre Wolkenstein, Jan M Friedman.   

Abstract

Multiple neurofibromas are cardinal features of neurofibromatosis 1 (NF1). Several different types of NF1-associated neurofibromas occur, each distinct in terms of pathological details, clinical presentation, and natural history. Mast cells are present in most neurofibromas and have been shown to be critical to the origin and progression of neurofibromas in both human NF1 and relevant mouse models. In this investigation, the authors determined whether mast cell involvement is the same for all types of NF1-associated neurofibromas. They examined the density and distribution of mast cells within 49 NF1-associated neurofibromas classified histopathologically as diffuse or encapsulated on the basis of the presence or absence of the perineurium or its constituent cells. They made two observations: (1) Diffuse neurofibromas had significantly higher densities of mast cells than did encapsulated neurofibromas, and (2) mast cells were evenly distributed throughout diffuse neurofibromas but were primarily restricted to the periphery of encapsulated neurofibromas. The differences in mast cell density and distribution differentiate the two basic types of NF1-associated neurofibromas, suggesting that the pathogenesis of diffuse and encapsulated neurofibromas may be significantly different.

Entities:  

Mesh:

Year:  2011        PMID: 21525187      PMCID: PMC3201189          DOI: 10.1369/0022155411407340

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  15 in total

1.  Ultrastructural evidence for mast cell activation in a case of neurofibromatosis.

Authors:  R Giorno; J Lieber; H N Claman
Journal:  Neurofibromatosis       Date:  1989

Review 2.  Mast cells and neurofibromatosis.

Authors:  R Giorno; H N Claman
Journal:  Neurofibromatosis       Date:  1988

Review 3.  National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987.

Authors: 
Journal:  Neurofibromatosis       Date:  1988

4.  Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen.

Authors:  V M Riccardi
Journal:  Arch Dermatol       Date:  1987-08

5.  Neurofibromas in NF1: Schwann cell origin and role of tumor environment.

Authors:  Yuan Zhu; Pritam Ghosh; Patrick Charnay; Dennis K Burns; Luis F Parada
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

6.  Mast cell and lymphoreticular infiltrates in neurofibromas. Comparison with nerve sheath tumors.

Authors:  M D Johnson; J Kamso-Pratt; C F Federspiel; W O Whetsell
Journal:  Arch Pathol Lab Med       Date:  1989-11       Impact factor: 5.534

7.  Discounting an adverse maternal effect on severity of neurofibromatosis.

Authors:  V M Riccardi; J S Wald
Journal:  Pediatrics       Date:  1987-03       Impact factor: 7.124

8.  Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.

Authors:  Feng-Chun Yang; David A Ingram; Shi Chen; Yuan Zhu; Jin Yuan; Xiaohong Li; Xianlin Yang; Scott Knowles; Whitney Horn; Yan Li; Shaobo Zhang; Yanzhu Yang; Saeed T Vakili; Menggang Yu; Dennis Burns; Kent Robertson; Gary Hutchins; Luis F Parada; D Wade Clapp
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

9.  Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells.

Authors:  V M Riccardi
Journal:  Birth Defects Orig Artic Ser       Date:  1981

Review 10.  The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions.

Authors:  J Bienenstock; M Tomioka; H Matsuda; R H Stead; G Quinonez; G T Simon; M D Coughlin; J A Denburg
Journal:  Int Arch Allergy Appl Immunol       Date:  1987
View more
  7 in total

Review 1.  Epigenetic mechanisms drive the progression of neurofibromas to malignant peripheral nerve sheath tumors.

Authors:  Krish Suresh; Tamara Kliot; Andrea Piunti; Michel Kliot
Journal:  Surg Neurol Int       Date:  2016-11-14

2.  The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.

Authors:  Frank L Rice; George Houk; James P Wymer; Sara J C Gosline; Justin Guinney; Jianqiang Wu; Nancy Ratner; Michael P Jankowski; Salvo La Rosa; Marilyn Dockum; James R Storey; Steven L Carroll; Phillip J Albrecht; Vincent M Riccardi
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.752

3.  Prognostic significance of mast cell and microvascular densities in malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1.

Authors:  Roberto André Torres de Vasconcelos; Pedro Guimarães Coscarelli; Thyago Marsicano Vieira; Washington Silva Noguera; Davy Carlos Mendes Rapozo; Marcus André Acioly
Journal:  Cancer Med       Date:  2019-02-08       Impact factor: 4.452

4.  Neurofibromin Deficiency and Extracellular Matrix Cooperate to Increase Transforming Potential through FAK-Dependent Signaling.

Authors:  Andrea Errico; Anna Stocco; Vincent M Riccardi; Alberto Gambalunga; Franco Bassetto; Martina Grigatti; Amedeo Ferlosio; Gianluca Tadini; Debora Garozzo; Stefano Ferraresi; Andrea Trevisan; Sandra Giustini; Andrea Rasola; Federica Chiara
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

5.  Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study.

Authors:  Emilie Sbidian; Smaïl Hadj-Rabia; Vincent M Riccardi; Laurence L Valeyrie-Allanore; Sébastien Barbarot; Olivier Chosidow; Salah Ferkal; Diana Rodriguez; Pierre Wolkenstein; Sylvie Bastuji-Garin
Journal:  Orphanet J Rare Dis       Date:  2012-09-03       Impact factor: 4.123

6.  Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients.

Authors:  Said Farschtschi; Su-Jin Park; Birgit Sawitzki; Su-Jun Oh; Lan Kluwe; Victor F Mautner; Andreas Kurtz
Journal:  Cancer Immunol Immunother       Date:  2016-07-23       Impact factor: 6.968

7.  Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.

Authors:  Jineta Banerjee; Robert J Allaway; Jaclyn N Taroni; Aaron Baker; Xiaochun Zhang; Chang In Moon; Christine A Pratilas; Jaishri O Blakeley; Justin Guinney; Angela Hirbe; Casey S Greene; Sara Jc Gosline
Journal:  Genes (Basel)       Date:  2020-02-21       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.